BAGLIVO, SARA
 Distribuzione geografica
Continente #
NA - Nord America 717
AS - Asia 552
EU - Europa 473
SA - Sud America 127
AF - Africa 11
OC - Oceania 1
Totale 1.881
Nazione #
US - Stati Uniti d'America 691
SG - Singapore 259
CN - Cina 117
IE - Irlanda 109
BR - Brasile 107
IT - Italia 97
HK - Hong Kong 75
DE - Germania 70
RU - Federazione Russa 50
VN - Vietnam 36
RO - Romania 27
KR - Corea 25
FI - Finlandia 24
FR - Francia 21
GB - Regno Unito 14
CA - Canada 12
AT - Austria 11
PL - Polonia 11
ES - Italia 10
IN - India 10
MX - Messico 10
AR - Argentina 9
SE - Svezia 9
JP - Giappone 8
CH - Svizzera 5
NL - Olanda 5
ZA - Sudafrica 5
EC - Ecuador 4
BD - Bangladesh 3
IQ - Iraq 3
MA - Marocco 3
PY - Paraguay 3
TR - Turchia 3
UZ - Uzbekistan 3
GR - Grecia 2
ID - Indonesia 2
LT - Lituania 2
UA - Ucraina 2
AE - Emirati Arabi Uniti 1
BE - Belgio 1
BG - Bulgaria 1
BO - Bolivia 1
CL - Cile 1
CO - Colombia 1
DO - Repubblica Dominicana 1
EG - Egitto 1
GA - Gabon 1
HU - Ungheria 1
IR - Iran 1
JM - Giamaica 1
MN - Mongolia 1
NP - Nepal 1
PE - Perù 1
PH - Filippine 1
PK - Pakistan 1
PW - Palau 1
RS - Serbia 1
SA - Arabia Saudita 1
SO - Somalia 1
SV - El Salvador 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
Totale 1.881
Città #
Singapore 176
Chandler 145
Dublin 109
Hong Kong 74
Ashburn 43
San Mateo 35
Boardman 34
Munich 33
Santa Clara 33
Perugia 32
Beijing 31
Bucharest 27
Seoul 25
Altamura 21
Los Angeles 21
Lawrence 20
Medford 20
Princeton 20
Ann Arbor 14
Helsinki 14
Moscow 13
New York 13
Ho Chi Minh City 12
Andover 11
Warsaw 11
Wilmington 11
São Paulo 10
Des Moines 9
Frankfurt am Main 9
Piscataway 9
Falkenstein 8
Tokyo 8
Mexico City 7
Nuremberg 7
Stockholm 7
Hefei 6
San Paolo di Civitate 6
Seattle 6
Chennai 5
Hanoi 5
Houston 5
Redmond 5
Turku 5
Vienna 5
Arezzo 4
Brasília 4
Brooklyn 4
Curitiba 4
Dearborn 4
Denver 4
Guangzhou 4
Haiphong 4
Johannesburg 4
Montreal 4
Nanjing 4
Phoenix 4
Rio de Janeiro 4
Saint Petersburg 4
San Francisco 4
The Dalles 4
Amsterdam 3
Ankara 3
Atlanta 3
Calgary 3
Formia 3
Paris 3
Poplar 3
Rome 3
Tianjin 3
Anápolis 2
Bexley 2
Boston 2
Chicago 2
Columbus 2
Erbil 2
Faenza 2
Foligno 2
Governador Valadares 2
Guayaquil 2
Lappeenranta 2
Londrina 2
Manchester 2
Mumbai 2
Norfolk 2
Orem 2
Patos de Minas 2
Phủ Lý 2
Qingdao 2
Redwood City 2
Roubaix 2
Simi Valley 2
São José do Rio Preto 2
Terni 2
Toronto 2
Vicenza 2
Vilnius 2
Wuhan 2
Agadir 1
Amelia 1
Angeles 1
Totale 1.270
Nome #
Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer 108
Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib 90
Non-coding RNAs in lung cancer 88
Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer 87
Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence 85
High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients 81
Higher tlr7 gene expression predicts poor clinical outcome in advanced nsclc patients treated with immunotherapy 79
Targeting the KRAS variant for treatment of non-small cell lung cancer: Potential therapeutic applications 78
Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study 78
Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations 76
Osimertinib 75
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib 74
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy 72
Dynamic network topologies analysis in proteomics data of NSCLC cell lines using a new pipeline based on machine learning tools 70
KRAS mutation and DNA repair and synthesis genes in non-small-cell lung cancer 70
Sensitivity to immune checkpoint blockade in advanced non-small cell lung cancer patients with EGFR exon 20 insertion mutations 67
MiRNAs and resistance to EGFRâ€"TKIs in EGFR-mutant non-small cell lung cancer: Beyond 'traditional mechanisms' of resistance 66
Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence 62
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer 59
Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient. 58
Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer 54
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab 53
Detection of egfr mutations in plasma cell-free tumor dna of tki-treated advanced-nsclc patients by three methodologies: Scorpion-arms, pnaclamp, and digital pcr 53
Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review 48
RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature 43
Lorlatinib beyond progression plus platinum/pemetrexed for ALK-positive non-small cell lung cancer patients: report of two cases 41
Correction: Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer (Oncology and Therapy, (2024), 12, 1, (163-171), 10.1007/s40487-023-00251-6) 40
Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations 39
Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs 36
Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression 33
Totale 1.963
Categoria #
all - tutte 9.822
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.822


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202116 0 0 0 0 0 1 1 6 3 1 4 0
2021/2022170 1 25 1 5 4 3 1 47 2 22 24 35
2022/2023398 22 75 9 37 38 40 0 18 142 0 14 3
2023/2024158 8 10 16 6 2 2 39 1 4 5 36 29
2024/2025418 10 31 31 12 46 33 9 32 70 34 67 43
2025/2026642 65 97 72 185 198 25 0 0 0 0 0 0
Totale 1.963